Discussions – 4.6 | Drug Discovery & Pharma – AIiHC ORG

Toggle Side Panel

Home
About Us

Our Story
Community

1. Stakeholder Connect

1.1 Clinician's forum

1.2 Healthcare leaders

1.3 AI Innovators & Developers

1.4 Policy, Regulatory experts

1.5 IT & Infrastructure Management

1.6 Industry & Solution Providers

1.7 Patients & Caregivers

2. AI Adoption cycle

2.1 Exploration and Readiness

2.2 Implementation & Integration

2.3 Monitoring & Optimization

2.4 Future & Emerging AI

3. Ethics & Governances

3.1 Ethical AI & Fairness

3.2 Data Governance & Security

3.3 Regulatory Landscape

3.4 Standards and Best Practices

4. Clinical Domains

4.1 Medical AI

4.2 Surgical AI

4.3 Diagnostic Imaging AI

4.4 Primary Care & Family Medicine

4.5 Medical and Behavioural Health

4.6 Drug Discovery & Pharma

4.7 Public & Population Health

4.8 Hospital System Operations

5. Academics

5.1 Research Project Collaboration

5.2 Grant & Funding Opportunities

5.3 Clinical Trials & Academic Studies

5.4 University & Institution Connect

5.5 Research Methodologies & Tools

5.6 Education & Workforce development

6. Industry Exchange

6.1 AI Application Vendors

6.2 Platform & Infrastructure Providers

6.3 Implementation & Consultancy Partners

6.4 MedTech, Pharma & Device Innovators

6.5 Responsible Industry Practices
Discussions
Contact us

Sign in

Search for:

Home
About Us
Community
Discussions
Contact us

Search for:

4.6 | Drug Discovery & Pharma

Public AI in Clinical Domain

Public AI in Clinical Domain

Active 3 months ago

Purpose: AI’s role in accelerating drug development, from target identification to clinical trial... View more

Public AI in Clinical Domain

Organizer:

Organized by

Group Description

Purpose: AI’s role in accelerating drug development, from target identification to clinical trial optimization.

Description: This group explores how AI and machine learning are transforming the pharmaceutical industry, enhancing efficiency and success rates across the entire drug discovery and development pipeline.

Intended Use: For pharmaceutical researchers, drug developers, AI developers, and academics to discuss specific AI algorithms and strategies impacting drug design, preclinical research, clinical trials, and drug repurposing.

Limitations: Not for general AI model development (that’s 1.3). Not for direct patient care applications. Focus is on AI within the pharmaceutical and drug discovery domain.

Key Activities:Sharing breakthroughs in AI-driven target identification.Discussing AI’s impact on optimizing clinical trial design and patient selection.Exploring AI for drug repurposing and accelerating R&D.Debating ethical considerations in AI-accelerated drug development.

Potential Users: Academic/Researcher, AI Innovator/Developer, Industry/Solution Provider (Pharma/Biotech).

Possible Discussions: “Using AI to identify novel drug targets for oncology,” “AI-powered prediction of drug toxicity,” “The role of AI in accelerating vaccine development.”

Leave Group

Are you sure you want to leave ?

Cancel Confirm

Subgroups
Feed
Members
Documents
Discussions

All Discussions
Sorry, there were no discussions found.

You must be logged in to create new discussions.

© 2025 - AI Healthcare Community

Disclaimer
Rules And Regulation
Community Guidelines
Terms of Use
Privacy Policy

Report

There was a problem reporting this post.

Harassment Harassment or bullying behavior

Inappropriate Contains mature or sensitive content

Misinformation Contains misleading or false information

Offensive Contains abusive or derogatory content

Suspicious Contains spam, fake content or potential malware

Other

Report note

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

See blocked member's posts
Mention this member in posts
Invite this member to groups
Message this member
Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .